278 completed, 51 terminated, 36 recruiting, 25 active not recruiting. 192 Phase 2, 157 Phase 3, 22 Not applicable, 11 Phase 1, 1 Phase 4.
Follow SWOG Cancer Research Network: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Adding Surgery and Radiation to the Usual Treatment for HER2-Positive Breast Cancer That Had Already Spread at Diagnosis Biopsy Procedure, Biospecimen Collection, Breast Conservation Treatment - Anatomic Stage IV Breast Cancer AJCC v8, Metastatic HER2-Positive Breast Carcinoma | Phase 3 | Recruiting | SWOG Cancer Research Network | 562 | 2027-03-09 | 2026-10-13 |
| Testing Short-Course Radiation Versus Standard-Course Radiation for Soft Tissue Sarcomas That Need Surgery and Radiation 3-Dimensional Conformal Radiation Therapy, Biospecimen Collection, Computed Tomography - Recurrent Soft Tissue Sarcoma of the Trunk and Extremities, Resectable Soft Tissue Sarcoma of the Trunk and Extremities | Phase 3 | Recruiting | SWOG Cancer Research Network | 296 | 2026-12-02 | 2026-10-13 |
| A Pilot Unrestricted Payment Program for Early-stage Cancer Patients: the PAYMENT Trial Electronic Health Record Review, Interview, Support - Malignant Solid Neoplasm | Not applicable | Recruiting | Fred Hutchinson Cancer Center | 20 | 2026-11-15 | 2026-10-20 |
| Comparing Momelotinib and Ruxolitinib in People With Untreated Myelofibrosis and Low Blood Cell Counts Momelotinib, Ruxolitinib - Myelofibrosis, Myelofibrosis (MF) | Phase 4 | Not yet recruiting | SWOG Cancer Research Network | 268 | 2026-11-01 | 2026-09-17 |
| Adding Capivasertib to Standard Treatment in HR Positive, HER2 Negative Metastatic Breast Cancer Based on ctDNA Testing NSAI + CDK4/6i, NSAI + CDK4/6i + Capivasertib, Fulvestrant + CDK4/6i + Capivasertib - HR Positive/HER-2 Negative Breast Cancer | Phase 3 | Not yet recruiting | SWOG Cancer Research Network | 1084 | 2026-10-30 | 2026-09-03 |
| Testing Blinatumomab With or Without Revumenib in Patients With B-cell Acute Lymphoblastic Leukemia With a Genetic Change Requiring More Treatment Biospecimen Collection, Blinatumomab, Bone Marrow Aspiration - Acute Leukemia of Ambiguous Lineage, B Acute Lymphoblastic Leukemia | Phase 2 | Not yet recruiting | SWOG Cancer Research Network | 90 | 2026-10-14 | 2026-10-13 |
| Testing Mosunetuzumab Alone, With Zanubrutinib, or With Polatuzumab Vedotin for Treating Marginal Zone Lymphoma That Came Back or Didn't Get Better With Treatment Biospecimen Collection, Bone Marrow Biopsy, Computed Tomography - Recurrent Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue, Recurrent Nodal Marginal Zone Lymphoma | Phase 2 | Not yet recruiting | SWOG Cancer Research Network | 138 | 2026-10-03 | 2026-10-13 |
| Treatment for Advanced Non-small Cell Lung Cancer With Actionable Genomic Alterations After Targeted Treatment and Chemotherapy (An Expanded Lung-MAP Treatment Trial) Biospecimen Collection, Computed Tomography, Ivonescimab - Recurrent Lung Non-Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8 | Phase 2 | Recruiting | SWOG Cancer Research Network | 117 | 2026-09-22 | 2026-10-13 |
| Testing an Educational Program to Improve Goals of Care Conversations Between Patients and Their Care Teams Best Practice, Educational Intervention, Electronic Health Record Review - Malignant Solid Neoplasm | Not applicable | Recruiting | SWOG Cancer Research Network | 1020 | 2026-08-07 | 2026-10-09 |
| Adding Pirtobrutinib to the Usual Treatment for People With Newly Diagnosed Richter Transformation, The PIRAMID Trial Biospecimen Collection, Computed Tomography, Cyclophosphamide - Richter Syndrome, Transformed Chronic Lymphocytic Leukemia to Diffuse Large B-Cell Lymphoma | Phase 3 | Recruiting | SWOG Cancer Research Network | 102 | 2026-08-04 | 2026-10-13 |
| Adding Biotherapy or Placebo to Standard Treatment for Advanced Kidney Cancer Axitinib, Biospecimen Collection, Bone Scan - Advanced Clear Cell Renal Cell Carcinoma, Metastatic Clear Cell Renal Cell Carcinoma | Phase 3 | Recruiting | SWOG Cancer Research Network | 718 | 2026-06-05 | 2026-06-11 |
| Studying Chemotherapy With or Without Panitumumab for Unresectable, Locally Advanced, or Metastatic Pancreatic Cancer Without KRAS Mutations Biospecimen Collection, Computed Tomography, Fluorouracil - Locally Advanced Pancreatic Adenocarcinoma, Metastatic Pancreatic Adenocarcinoma | Phase 3 | Recruiting | SWOG Cancer Research Network | 94 | 2026-05-13 | 2026-05-22 |
| Adding Asciminib to Usual Treatment for Adults With Newly Diagnosed Philadelphia Chromosome Positive (Ph+) Acute Lymphoblastic Leukemia Induction Phase, Re-Induction Phase, Post-Remission - Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia, CD19+ Acute Leukemia | Phase 2 | Enrolling by invitation | SWOG Cancer Research Network | 55 | 2026-04-13 | 2026-10-05 |
| Combined Amivantamab, Carboplatin and Paclitaxel in Unresectable Locally Recurrent or Metastatic Head and Neck Cancer Amivantamab Subcutaneous and Co-Formulated with Recombinant Human Hyaluronidase (SC CF) - Head &Amp; Neck Cancer, Head &Amp; Neck Squamous Cell Carcinoma | Phase 2 | Enrolling by invitation | SWOG Cancer Research Network | 50 | 2026-03-25 | 2026-10-05 |
| Radiotherapy to Block Oligoprogression In Metastatic Non-Small-Cell Lung Cancer SBRT, First or second-line standard of care therapy - Non-small Cell Lung Cancer | Phase 3 | Recruiting | Canadian Cancer Trials Group | 320 | 2025-12-16 | 2026-07-14 |
| Using Biomarker Tests to Select and Test New, Personalized Treatments for Extensive Stage Small Cell Lung Cancer, PRISM Study Biospecimen Collection, Ceralasertib, Computed Tomography - Extensive Stage Lung Small Cell Carcinoma, Lung Small Cell Carcinoma, A Subtype | Phase 2 | Recruiting | SWOG Cancer Research Network | 900 | 2025-11-06 | 2026-03-30 |
| Evaluating Whether an Educational Website Called Current Together After Cancer (CTAC) Improves Follow-up Care for Colorectal Cancer Survivors Intervention website access, Control website access, Interview - Colorectal Cancer Stage II, Colorectal Cancer Stage III | Phase 3 | Recruiting | SWOG Cancer Research Network | 1057 | 2025-10-15 | 2026-03-31 |
| Docetaxel to Androgen Receptor Pathway Inhibitors in Patients With Metastatic Castration Sensitive Prostate Cancer and Suboptimal PSA Response Abiraterone, Enzalutamide, Apalutamide - Prostate Cancer (Adenocarcinoma) | Phase 3 | Recruiting | Canadian Cancer Trials Group | 830 | 2025-05-28 | 2026-07-14 |
| Adding the Immunotherapy Drug Cemiplimab to Usual Treatment for People With Advanced Non-Small Cell Lung Cancer Who Had Previous Treatment With Platinum Chemotherapy and Immunotherapy (An Expanded Lung-MAP Treatment Trial) Biospecimen Collection, Cemiplimab, Computed Tomography - Recurrent Lung Non-Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8 | Phase 2 / Phase 3 | Recruiting | SWOG Cancer Research Network | 378 | 2025-05-22 | 2026-10-09 |
| Lanreotide Versus Placebo Before Surgery to Prevent a Surgical Complication Called a Pancreatic Fistula Biospecimen Collection, Distal Pancreatectomy, Lanreotide - Pancreatic Carcinoma, Pancreatic Neoplasm | Phase 3 | Recruiting | SWOG Cancer Research Network | 274 | 2025-05-09 | 2026-03-31 |
Showing 20 of 416. Sign in to see all of them.
Breast Neoplasms (61) · Lung Neoplasms (50) · Carcinoma, Non-Small-Cell Lung (48) · Lymphoma (37) · Prostatic Neoplasms (31) · Leukemia (30) · Colorectal Neoplasms (20) · Multiple Myeloma (19) · Rectal Neoplasms (19) · Adenocarcinoma of Lung (17) · Head and Neck Neoplasms (17) · Lymphoma, Large B-Cell, Diffuse (17) · Colonic Neoplasms (16) · Leukemia, Myeloid, Acute (16) · Neoplasm Metastasis (16)
Radiotherapy (52) · Cyclophosphamide (50) · Cisplatin (43) · Doxorubicin (41) · Docetaxel (37) · Paclitaxel (37) · Fluorouracil (29) · Gemcitabine (28) · Carboplatin (27) · Filgrastim (26) · Vincristine (26) · Etoposide (25) · Prednisone (25) · Dexamethasone (23) · Specimen Handling (23)
United States (351) · Canada (71) · Puerto Rico (24) · Mexico (11) · South Africa (11) · Australia (9) · Peru (9) · Guam (8) · Chile (5) · Colombia (5) · United Kingdom (5) · Switzerland (4) · Ireland (3) · New Zealand (3) · Saudi Arabia (3)
Vassiliki Papadimitrakopoulou (9) · Kathy S. Albain, MD (8) · Primo N. Lara, MD (7) · Dawn Hershman, MD (6) · James N. Ingle, MD (6) · Oliver W. Press, MD, PhD (6) · Robert P. Whitehead, MD (6) · Laurence H. Klotz, MD (5) · Maha Hadi A. Hussain, MD (5) · Silvana Martino, DO (5) · Anjali Advani, MD (4) · Cheryl L. Willman, MD (4) · Daniel P. Petrylak, MD (4) · Eric J. Small, MD (4) · Jerry Radich, MD (4)
PMID 24383844, PMID 25527568, PMID 27519183, PMID 33853037, PMID 27264120, PMID 28586789, PMID 29618479, PMID 35787017, PMID 38979716, PMID 39621968, PMID 10604271, PMID 11241082, PMID 11289126, PMID 11448906, PMID 11560968, PMID 11586105, PMID 11709567, PMID 12121233, PMID 12149294, PMID 12177096, PMID 12448660, PMID 12525193, PMID 12738671, PMID 12814333, PMID 12829663, PMID 12972528, PMID 14508361, PMID 14551341, PMID 14645636, PMID 14747052, PMID 15073859, PMID 15128893, PMID 15251940, PMID 15297403, PMID 15308571, PMID 15328179, PMID 15452834, PMID 15470214, PMID 15484217, PMID 15625363, PMID 15713522, PMID 15721401, PMID 15756004, PMID 15774775, PMID 15791454, PMID 15860488, PMID 15908667, PMID 15923572, PMID 15972865, PMID 16033132
U10CA032102 (202), U10CA180888 (62), U10CA037429 (24), UG1CA189974 (19), U10CA031946 (6), U10CA025224 (5), U10CA021115 (4), U10CA180821 (4), U10CA012027 (3), U10CA023318 (3), U10CA180820 (3), 2004 (1), 2005 (1), N01CM17003 (1), P30CA016087 (1)